

JUL -7 1997

510(k) Summary of Safety and Effectiveness Information**Dade® TRU-Liquid™ Bilirubin Control****June 17, 1997**

Dade International Inc.
2173 N.W. 99th Avenue
Miami, FL 33172

Contact Person: Radha Goolabsingh at 305-392-5621 or Marilyn Waxberg at 305-392-5614, or
by facsimile at 305-392-5622.

Trade or Proprietary Name: Dade® TRU-Liquid™ Bilirubin Control
Levels 1,2 and 3.

Common or Usual Name: Liquid Tri-Level Bilirubin Control

Classification Name: Quality Control Material (Assayed and Unassayed)

Registration Number: *Manufacturer*

Dade International Inc.
2173 N.W. 99th Avenue
Miami, FL 33172

1025506

Dade International Inc.
1851 Delaware Parkway
Miami, Florida 33125

1017272

The proposed Dade® TRU-Liquid™ Bilirubin Control is substantially equivalent to the ChemTrak Liquid Bilirubin Control manufactured by Medical Analysis Systems, previously cleared under Document Control No., K833097, on 1/11/84. The proposed and the predicate device are intended for use as assayed quality control materials to monitor accuracy and precision in the clinical assay of bilirubin



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

JUL - 7 1997

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

Marilyn S. Waxburg
• Director
Regulatory Affairs
Dade International, Inc.
2173 N.W. 99th Avenue
Miami, FL 33172

Re: K972287
Dade® TRU-Liquid™ Bilirubin Control
Regulatory Class: I
Product Code: JJX
Dated: June 17, 1997
Received: June 19, 1997

Dear Ms. Waxburg:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal Laws or Regulations.


Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,



Steven I. Gutman, M.D., M.B.A.
Director
Division of Clinical
Laboratory Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

510(k) Number (if known): _____


Device Name: Dade TRU-Liquid Bilirubin Control

Indications For Use:

Dade TRU-Liquid Bilirubin Control is intended for use as an assayed quality control material in clinical laboratory quality assurance programs and in the monitoring of accuracy and precision in the clinical laboratory assay of bilirubin.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)



Division Sign-Off)
Division of Clinical Laboratory Devices
Number 6342

Prescription Use ☒
(Per 21 CFR 801.109)

OR

Over-The-Counter Use _____

(Optional Format 1-2-96)